Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

Joseph Curry, Jennifer Johnson, Patrick Tassone, Marina Domingo Vidal, Diana Whitaker Menezes, John Sprandio, Mehri Mollaee, Paolo Cotzia, Ruth Birbe, Zhao Lin, Kurren Gill, Elizabeth Duddy, Tingting Zhan, Benjamin Leiby, Michelle Reyzer, David Cognetti, Adam Luginbuhl, Madalina Tuluc, Ubaldo Martinez-Outschoorn, Joseph Curry, Jennifer Johnson, Patrick Tassone, Marina Domingo Vidal, Diana Whitaker Menezes, John Sprandio, Mehri Mollaee, Paolo Cotzia, Ruth Birbe, Zhao Lin, Kurren Gill, Elizabeth Duddy, Tingting Zhan, Benjamin Leiby, Michelle Reyzer, David Cognetti, Adam Luginbuhl, Madalina Tuluc, Ubaldo Martinez-Outschoorn

Abstract

Objective: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors.

Study design: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full-treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery.

Methods: Immunohistochemistry (IHC) for the metabolic markers caveolin-1 (CAV1), B-galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki-67 IHC, were performed in pre- and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects.

Results: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4-fold postmetformin (P < 0.05), as measured by MSI.

Conclusion: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment.

Level of evidence: 4. Laryngoscope, 127:1808-1815, 2017.

Trial registration: ClinicalTrials.gov NCT02083692.

Keywords: Head and neck cancer; metformin; squamous cell carcinoma; tumor metabolism.

© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Figures

Figure 1
Figure 1
(A–B). Effect of metformin on stromal CAV1 and GALB expression in HNSCC. CAV1 and GALB immunostaining were performed on paired premetformin (A and B, respectively) and postmetformin HNSCC samples, and a representative example is shown. Note that there is a postmetformin increase in CAV1 and GALB stromal staining. Original magnification: 40×. Waterfall plot of the change in CAV1 and GALB intensity between pre‐ and postmetformin samples also is shown. CAV1 = caveolin‐1; GALB = beta galactosidase; HNSCC = head and neck squamous cell carcinoma.
Figure 2
Figure 2
Effect of metformin on TUNEL staining in HNSCC. TUNEL was performed on paired premetformin and postmetformin HNSCC samples, and a representative example is shown. Note that there is a postmetformin increase in TUNEL staining in carcinoma cells. Original magnification: 40×. Waterfall plot of the change in GALB intensity between pre‐ and postmetformin samples also is shown. HNSCC = head and neck squamous cell carcinoma; TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labeling.
Figure 3
Figure 3
(A–C) Mass spectroscopy imaging (MSI) comparing carcinoma regions premetformin and postmetformin. Hematoxylin and eosin staining was performed on HNSCC samples, and carcinoma regions were marked in pre‐ and postmetformin samples. Original magnification: 40× (A). Carcinoma cells have a 2.4‐fold reduction in lactate levels postmetformin (post‐rx) compared to premetformin (pre‐rx) in all samples (P < 0.05). Lactate levels were measured by MSI in the carcinoma regions pre‐ and postmetformin, and results were compared for each patient (B). Note that the black lines are the tracings for the premetformin samples and the red lines for the postmetformin samples. Effects of metformin on the tumor microenvironment of HNSCC (C). The current clinical trial demonstrates in HNSCC that metformin has anticancer activity. Metformin in carcinoma cells increases apoptosis, as measured by terminal deoxynucleotidyl transferase dUTP nick end labeling, and increases lactate levels. Metformin also alters metabolic markers in stromal cells. The tumor stroma after metformin exposure has increased CAV1 and GALB expression, which are markers of reduced catabolism and increased senescence. CAV1 = caveolin‐1; GALB = beta galactosidase; HNSCC = head and neck squamous cell carcinoma; MSI = mass spectroscopy imaging; rx = treatment.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
    1. Kawecki A, Krajewski R. Follow‐up in patients treated for head and neck cancer. Memo 2014;7:87–91.
    1. Bann DV, Deschler DG, Goyal N. Novel immunotherapeutic approaches for head and neck squamous cell carcinoma. Cancers (Basel) 2016;8. pii: E87.
    1. Skinner HD, McCurdy MR, Echeverria AE, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013;52:1002–1009.
    1. Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014;36:1039–1043.
    1. Yen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck 2015;37:1268–1273.
    1. Rego DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol 2015;51:416–422.
    1. Pollak M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 2014;20:591–593.
    1. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953–966.
    1. Martinez‐Outschoorn UE, Peiris‐Pagés M, Pestell RG, Sotgia F, Lisanti MP. Nat Rev Clin Oncol. 2017;14:11–31. doi:10.1038/nrclinonc.2016.60. Review. PMID: 27141887
    1. El‐Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223–228.
    1. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti‐diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607–614.
    1. Wheaton WW, Weinberg SE, Hamanaka RB, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 2014;3:e02242.
    1. Chandel NS, Avizonis D, Reczek CR, et al. Are Metformin doses used in murine cancer models clinically relevant? Cell Metab 2016;23:569–570.
    1. Andrzejewski S, Gravel SP, Pollak M, St‐Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014;2:12.
    1. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542–546.
    1. Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F. In vitro and in vivo anti‐tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012;12:517.
    1. Harada K, Ferdous T, Harada T, Ueyama Y. Metformin in combination with 5‐fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. Int J Oncol 2016;49:276–284.
    1. Ueno S, Kimura T, Yamaga T, et al. Metformin enhances anti‐tumor effect of L‐type amino acid transporter 1 (LAT1) inhibitor. J Pharmacol Sci 2016;131:110–117.
    1. Martinez‐Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer‐associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 2014;25:47–60.
    1. Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res 2015;21:680–686.
    1. DeNicola GM, Cantley LC. Cancer's fuel choice: new flavors for a picky eater. Mol Cell 2015;60:514–523.
    1. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364–373.
    1. Martinez‐Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells “fuel” cancer cell mitochondria. Cell Metab 2012;15:4–5.
    1. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012;12:685–698.
    1. Marchiq I, Pouyssegur J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H symporters. J Mol Med (Berl) 2016;94:155–171.
    1. Curry JM, Tuluc M, Whitaker‐Menezes D, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 2013;12:1371–1384.
    1. Jensen DH, Therkildsen MH, Dabelsteen E. A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts. J Oral Pathol Med 2015;44:714–721.
    1. Curry JM, Sprandio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol 2014;41:217–234.
    1. Martinez‐Outschoorn UE, Sotgia F, Lisanti MP. Caveolae and signalling in cancer. Nat Rev Cancer 2015;15:225–237.
    1. Pavlides S, Whitaker‐Menezes D, Castello‐Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009;8:3984–4001.
    1. Asterholm IW, Mundy DI, Weng J, Anderson RG, Scherer PE. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin‐1. Cell Metab 2012;15:171–185.
    1. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry—looking beyond classical histology. Nat Rev Cancer 2010;10:639–646.
    1. Van de Plas R, Yang J, Spraggins J, Caprioli RM. Image fusion of mass spectrometry and microscopy: a multimodality paradigm for molecular tissue mapping. Nat Methods 2015;12:366–372.
    1. Taverna D, Pollins AC, Sindona G, Caprioli RM, Nanney LB. Imaging mass spectrometry for accessing molecular changes during burn wound healing. Wound Repair Regen 2016;24:775–785.
    1. Strohalm M, Hassman M, Kosata B, Kodicek M. mMass data miner: an open source alternative for mass spectrometric data analysis. Rapid Commun Mass Spectrom 2008;22:905–908.
    1. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135:821–830.
    1. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short‐term clinical trial. Cancer Prev Res (Phila) 2010;3:1077–1083.
    1. Cazzaniga M, DeCensi A, Pruneri G, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013;109:2792–2797.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
    1. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle 2012;11:1374–1382.
    1. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation‐induced senescence. Clin Cancer Res 2012;18:290–300.
    1. Vitale‐Cross L, Molinolo AA, Martin D, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen‐induced premalignant lesions. Cancer Prev Res (Phila) 2012;5:562–573.
    1. Woo SH, Sandulache VC, Yang L, Skinner HD. Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival. Methods Mol Biol 2014;1165:11–18.
    1. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2‐deoxyglucose induces p53‐dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465–2475.
    1. Tomic T, Botton T, Cerezo M, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011;2:e199.
    1. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013;123:3693–3700.
    1. Gronroos TJ, Lehtio K, Soderstrom KO, et al. Hypoxia, blood flow and metabolism in squamous‐cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer 2014;14:876.
    1. Javeshghani S, Zakikhani M, Austin S, et al. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res 2012;72:6257–6267.
    1. Birsoy K, Possemato R, Lorbeer FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014;508:108–112.
    1. Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis 2015;6:e1675.
    1. Sotgia F, Martinez‐Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin‐1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012;7:423–467.
    1. Harris AL. Metabolic compartments in tumor tissue: implications for therapy. Cell Cycle 2012;11:13–14.
    1. Martinez‐Outschoorn UE, Pavlides S, Whitaker‐Menezes D, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin‐1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010;9:2423–2433.
    1. Bartholomew JN, Volonte D, Galbiati F. Caveolin‐1 regulates the antagonistic pleiotropic properties of cellular senescence through a novel Mdm2/p53‐mediated pathway. Cancer Res 2009;69:2878–2886.
    1. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013;75:685–705.
    1. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363–9367.
    1. Kim YM, Seo YH, Park CB, Yoon SH, Yoon G. Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence. Ann N Y Acad Sci 2010;1201:65–71.
    1. Ros S, Schulze A. Linking glycogen and senescence in cancer cells. Cell Metab 2012;16:687–688.
    1. Favaro E, Bensaad K, Chong MG, et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 2012;16:751–764.
    1. Kaplon J, Zheng L, Meissl K, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene‐induced senescence. Nature 2013;498:109–112.
    1. Li M, Durbin KR, Sweet SM, Tipton JD, Zheng Y, Kelleher NL. Oncogene‐induced cellular senescence elicits an anti‐Warburg effect. Proteomics 2013;13:2585–2596.
    1. Salmenpera P, Karhemo PR, Rasanen K, Laakkonen P, Vaheri A. Fibroblast spheroids as a model to study sustained fibroblast quiescence and their crosstalk with tumor cells. Exp Cell Res 2016;345:17–24.
    1. Bovenzi CD, Hamilton J, Tassone P, et al. Prognostic indications of elevated MCT4 and CD147 across cancer types: a meta‐analysis. Biomed Res Int 2015;2015:242437.
    1. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre‐operative, window‐of‐opportunity, randomized trial. Breast Cancer Res Treat 2011;128:783–794.
    1. Dowling RJ, Lam S, Bassi C, et al. Metformin pharmacokinetics in mouse tumors: implications for human therapy. Cell Metab 2016;23:567–568.
    1. Sandulache VC, Skinner HD, Ow TJ, et al. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer 2012;118:711–721.
    1. Jinhua X, Ji W, Shouliang C, et al. Expression of immune checkpoints in T cells of esophageal cancer patients. Oncotarget 2016;7:63669–63678. doi: 10.18632/oncotarget.11611.
    1. Quan H, Fang L, Pan H, et al. An adaptive immune response driven by mature, antigen‐experienced T and B cells within the microenvironment of oral squamous cell carcinoma. Int J Cancer 2016;138:2952–2962.
    1. Economopoulou P, Kotsantis I, Psyrri A. Checkpoint inhibitors in head and neck cancer: rationale, clinical activity, and potential biomarkers. Curr Treat Options Oncol 2016;17:40.
    1. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune‐mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 2015;112:1809–1814.
    1. Tian Y, Tang B, Wang C, et al. Metformin mediates resensitivity to 5‐fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget 2016;7:46230–46241.
    1. Peng M, Huang Y, Tao T, et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. Sci Rep 2016;6:28611.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться